Splenectomy in β‐thalassemia patients: Practices and risks in a nationwide study

Documenti analoghi

• Luspatercept versus mitapivat for non‐transfusion‐dependent β‐thalassemia: Dare to compare?
  di: Khaled M. Musallam, et al.
  Pubblicazione: (2025)
• Interplay between α‐thalassemia and β‐hemoglobinopathies: Translating genotype–phenotype relationships into therapies
  di: Jim Vadolas, et al.
  Pubblicazione: (2024)
• Cerebral hemodynamics and oxygen metabolism in patients with milder and severe forms of sickle cell disease and thalassemia
  di: Liza Afzali‐Hashemi, et al.
  Pubblicazione: (2024)
• How I manage luspatercept in transfusion‐dependent beta‐thalassemia
  di: Daniele Lello Panzieri, et al.
  Pubblicazione: (2026)
• Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study
  di: Gian Matteo Rigolin, et al.
  Pubblicazione: (2024)